School of Chemistry and Chemical Engineering, South China University of Technology, 510640 Guangzhou, China.
Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, 510515 Guangzhou, China.
Nano Lett. 2023 Sep 27;23(18):8628-8636. doi: 10.1021/acs.nanolett.3c02466. Epub 2023 Sep 11.
Magnetic resonance imaging (MRI) is an important tool in the diagnosis of many cancers. However, clinical gadolinium (Gd)-based MRI contrast agents have limitations, such as large doses and potential side effects. To address these issues, we developed a hydrogen-bonded organic framework-based MRI contrast agent (PFC-73-Mn). Due to the hydrogen-bonded interaction of water molecules and the restricted rotation of manganese ions, PFC-73-Mn exhibits high longitudinal relaxation (5.03 mM s) under a 3.0 T clinical MRI scanner. A smaller intravenous dose (8 μmol of Mn/kg) of PFC-73-Mn can provide strong contrast and accurate diagnosis in multiple kinds of cancers, including breast tumor and ultrasmall orthotopic glioma. PFC-73-Mn represents a prospective new approach in tumor imaging, especially in early-stage cancer.
磁共振成像（MRI）是诊断多种癌症的重要工具。然而，临床用的钆（Gd）基 MRI 造影剂存在剂量大、潜在副作用等问题。为了解决这些问题，我们开发了一种基于氢键有机框架的 MRI 造影剂（PFC-73-Mn）。由于水分子的氢键相互作用和锰离子的受限旋转，PFC-73-Mn 在 3.0T 临床 MRI 扫描仪下表现出高纵向弛豫率（5.03mM·s-1）。较小的静脉注射剂量（8μmol Mn/kg）的 PFC-73-Mn 可以在多种癌症中提供强烈的对比和准确的诊断，包括乳腺癌和超小原位神经胶质瘤。PFC-73-Mn 代表了肿瘤成像的一种有前景的新方法，特别是在早期癌症。
